Stimulant Prescribing Training Guide Completion of a ‘Notification of Treatment using Stimulant Medication’ form.

Slides:



Advertisements
Similar presentations
Common/shared responsibilities between jobs.
Advertisements

Patient group directions. Dietitians prescribing.
Community Pharmacy Workbook
Developing an Individual Health Care Plan in NSW Public Schools Developing and implementing individual health care plans for students with complex health.
COMMUNITY PHARMACY WORKBOOK PUBLIC HEALTH DORSET
National Adult Clozapine Titration Chart
Successful Solutions Professional Development LLC Chapter 3 Medication Management.
State-by-State Treatment of Obesity Interventions Christine Ferguson Professor George Washington University School of Public Health and Health Services.
Therapeutic Formula Training Part 2 Working with Medi-Cal May 2013.
DMAS Office of Behavioral Health
Controlling Off-Label Narcotics Usage - Impact of New Arizona Legislation ARS §
Continuous Opioid Infusion Chart – adult Education Slide Presentation A presentation prepared by the Pain Interest Group Nursing Issues in association.
Legal issues and medication in mental health nursing (Victorian) Drugs Poisons and Controlled Substances Regulations 2006 aims to maximise the benefits.
Pharmacology Information, Rules, and Laws For Medications
Patient Group Directions Jane Swan Senior Medicines Management Advisor Nursing and Governance Health Partnerships.
Prescribing in Practice Part 2e Licensing, Legal Categories and Group Activity.
MEDICATION SAFETY: Clozapine Initiation Chart Review
Medication Safety Standard 4 Part 3 – Documentation of Patient Information, Continuity of Medication Management Margaret Duguid, Pharmaceutical Advisor.
Calculating Resident Rent
Student Fitness to Practise
Created by CCTC HIPAA: Notice of Privacy Practices Policy in the Administrative Guide.
Medicines & Related Substances Amendment Bill: Protecting the Nation’s Health “The State must take reasonable legislative and other measures, within its.
You need to consider whether a Patient Group Direction (PGD) would be appropriate for an area of practice that involves the supply or administration of.
Unlicensed Medicines in Paediatrics Is there a problem ? Scottish Neonatal and Paediatric Pharmacist Group National Paediatric Pre- Registration Pharmacist.
Area 15 Ryan White Program
Richard Z Aramini, PharmD PGY-1 Pharmacy Practice Resident Bay Pines VA Healthcare Center.
Data protection and extension of patent rights TRIPS requirements & TRIPS-plus provisions Carlos Correa.
MEDICATION ADMINISTRATION Topic 1A Drug Schedules.
1. 2 Melinda Campopiano, MD Medical Officer Center for Substance Abuse Treatment Substance Abuse and Mental Health Services Administration U.S. Department.
Implementation of the Mental Health Act 2007 Section 12(2) Approved Doctors.
Request for tender Primary mental health services RFT101 ATAPS & MHSRRA Goulburn Valley and North East September 2015.
For Pain or Not for Pain: Methadone Madness
ACCESS TO MEDICINES - POLICY AND ISSUES
Tajikistan Making Opioids Available in Eastern Europe and Central Asia March 5-6, 2013 Vienna.
SUNY Oswego Human Subjects Committee Last Revised 10/28/2011.
Methods to Evaluate and Improve National Policy: Focus on 2011 WHO Guidelines and PPSG Global Policy Evaluation Aaron M. Gilson, MS, MSSW, PhD Research.
FleetBoston Financial HIPAA Privacy Compliance Agnes Bundy Scanlan Managing Director and Chief Privacy Officer FleetBoston Financial.
Texas State Board of Medical Examiners Bruce A. Levy, M.D., J.D.
New Zealand Pharmacy Services Andi Shirtcliffe B. Pharm, PG Dip (Clin) Pharm, Reg Pharm NZ Chief Advisor – Pharmacy, New Zealand Ministry of Health.
TAFE NSW -Technical and Further Education Commission BACHELOR OF EARLY CHILDHOOD EDUCATION AND CARE ECEYE208A – Manage a Service.
HRPP Policies & Forms Chapter Two Created/Revised for AAHRPP June 1, 2007.
Prescribing in Practice Part 1 (c)
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
The National Quality Standard The National Quality Standard (NQS) is a key aspect of the NQF and sets a national benchmark for early childhood education.
The Mental Health Act 2009 An Overview Jacob Alexander The Adelaide Pre-Vocational Psychiatry Program 2016.
C McCaughey, D McKelvey, J Stewart, C Mallon, P Scullin
ACCESS & AUTHORIZATION. HOUSEKEEPING Food Restrooms Cell phones and calls Questions.
Safe Management of Medicines Healthcare Help Telephone Orders Who When What How Why.
Medicated Assisted Treatment (MAT) Terry R. Jones Director of Behavioral Health.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Training guide Recording and handling of Schedule 8 drugs in hospital wards ( including healthcare services and other patient care settings)
Private and confidential Community Pharmacy Future Four-or-more medicines support service Update on progress and next steps Approved18 th June 2012 This.
PBS Data Flow Prescriptions are written by approved prescribers Drugs are supplied to patients by approved suppliers S90 pharmacies and Friendly societies.
ABC-MAP Act 191 of 2014 September 16, 2016 Pennsylvania’s Prescription Drug Monitoring Program (PA PDMP)
Incidental Medical Services (IMS) Department of
COMMUNITY PHARMACY WORKBOOK PUBLIC HEALTH DORSET
Collaborative Practice Agreements
The NHS Urgent Medicine Supply Advanced Service Pilot
Paediatric Medicine: The Paediatric Investigation Plan
Methotrexate in Psoriasis Shared Care Guidelines
Substance Addiction(Compulsory Assessment and Treatment) Act 2017 Processes relevant to Children and Young People
CHAPTER 4 Information Management in Pharmacy.
Prescription Drug Monitoring Program
The SMI Evaluation and Determination Process
2019 Medicare Part D Rule Opioid-related Provisions
Prescription Drug Monitoring Program
National Credentialing Forum 2019 San Diego, CA February
LEGAL REQUIREMENTS FOR ACT 13 OF 2006
COMMUNITY PHARMACY WORKBOOK 2019 PUBLIC HEALTH DORSET
Presentation transcript:

Stimulant Prescribing Training Guide Completion of a ‘Notification of Treatment using Stimulant Medication’ form

Objectives 1.Overview of the Stimulant Prescribing Code (SPC) 2.Completion of a ‘Notification of Treatment using Stimulant Medication’ form

Stimulant Prescribing Code Overview  Aim: To promote quality, safety and efficacy in patients and decrease instances of abuse  Regulatory control framework for stimulants requires prescribers initiating treatment to 1.Obtain a stimulant prescriber number 2.Notify the Department of Health when initiating, modifying or terminating stimulant therapy

How it all works Authorised stimulant prescriber Notification of treatment using stimulant medication Stimulant Prescribing Code Prescribing commences Application to prescribe Reviewed by Department of Health or Stimulants Assessment Panel Authorisation from CEO of Health Modification or termination of treatment Within criteria Outside criteria

Stimulant Prescribing Code Overview  Authorised prescribers can either: 1.Initiate treatment for patients meeting criteria set out in the Code (notification) or 2. Apply for prior authorisation for patients who fall outside the Code

1.Diagnosis: Must be specified 2.Age: Restrictions apply regarding prescription and supply to patients based on age 3.Dose: Patients must always be started on the lowest practicable dose and titrated accordingly  If <18 years of age  1mg/kg/day of dexamphetamine (up to maximum 60mg/day) and 2mg/kg/day of methylphenidate (up to maximum 120mg/day)  If >18 years of age  Up to: 60mg dexamphetamine daily and 120mg of methylphenidate daily 4.Co-morbidities: Prescription and supply cannot occur without prior authorisation in patients with the following i.History of psychosis ii.Diagnosis of bipolar disorder iii.History of substance abuse Substance abuse within the previous five years Currently registered drug addict Current participant in the Community Program for Opioid Pharmacotherapy iv.History of diversion/misuse of S8 medications with the previous five years Criteria set in the Code

‘Notification of Treatment using Stimulant Medication’ form  Required for each patient initiating stimulant treatment  Patient details  Notification type  Condition being treated  Stimulant and dose  Public sector clinic  Acknowledgement section  Authorised Stimulant Practitioner

Patient details  Take care to ensure no discrepancies occur regarding information  Indicate:  First name  Last name – please advise if there is a change in surname and indicate as follows: NEW (OLD)  Date of birth (DOB)  Full address (number, street, suburb, postcode)  Medicare number  Weight – required for children (<18years)  Gender

‘Notification of Treatment using Stimulant Medication’ form  Patient details  Notification type  Condition being treated  Stimulant and dose  Public sector clinic  Acknowledgement section  Authorised Stimulant Practitioner

Notification type  Notification: Mandatory for new patients who fall within the criteria; patient signature required  Re-notification: Mandatory to advise any changes since last notification for existing patients within criteria; no patient signature is required

Re-notification  Required when there is a change in:  Dose  Drug  Drug form  Nominated co-prescriber  Co-prescriber nomination relates both to the co-prescriber and their respective practice  If a change of practice location occurs, co-prescribing arrangements need to be amended  Authorised Stimulant Practitioner  Patient details

Notification Type  Termination: state reason for ceasing stimulant therapy in patient; no patient signature is required

Notification type  Application for authorisation to prescribe outside the criteria  Indicate reason  If patient is outside the criteria further documentation must be completed and submitted additional to the notification form; patient signature required

Additional application checklist  Required for all applications to prescribe outside the Stimulant Prescribing Code  Forms available at: _for_stimulant_prescribers.pm _for_stimulant_prescribers.pm  Respective checklists for:  Age (≥ 2 and < 4 years)  High dose – children  High dose – adult  History of bipolar disorder  History of psychosis  Co-morbid substance abuse

‘Notification of Treatment using Stimulant Medication’ form  Patient details  Notification type  Condition being treated  Stimulant and dose  Public sector clinic  Acknowledgement section  Authorised stimulant practitioner

Diagnosis/Primary Condition being treated  Diagnostic criteria ADHD must be diagnosed by either DSM-IV or ICD-10 criteria  Further information Prescribers must also specify if the patient is on any psychotropic medications 1.2.

Diagnosis/Primary condition being treated  Indicate Diagnosis:  ADHD  Narcolepsy  Depression  Brain damage  The Code states that patient diagnosis and treatment may only be identified and managed by a specialist as described in the following table: Diagnosis Specialist field – unless otherwise approved by the CEO of the Department of Health ADHD Paediatrics, psychiatry, child/adolescent psychiatry, neurology Narcolepsy Neurology, paediatric neurology, respiratory/sleep, thoracic medicine Depression Psychiatry, child/adolescent psychiatry Brain damage Neurology, paediatric neurology, rehabilitation

‘Notification of Treatment using Stimulant Medication’ form  Patient details  Notification type  Condition being treated  Stimulant and dose  Public sector clinic  Acknowledgement section  Authorised stimulant practitioner

Stimulant to be prescribed + total daily dose  Indicate  Stimulant to be prescribed/formulation  Dose – to be entered in mg/day and not number of tablets/capsules  E.g. Dexamphetamine 40mg/day or Methylphenidate 60mg/day  Note:  All patients must be started on a low dose and titrated according to the patient response  If the patient is <18 years of age, doses must not exceed 1mg/kg/day of dexamphetamine (up to 60mg/day) and 2mg/kg/day of methylphenidate (up to 120mg/day)  If the patient is >18 years of age, doses must not exceed 60mg dexamphetamine daily and 120mg of methylphenidate daily

‘Notification of Treatment using Stimulant Medication’ form  Patient details  Notification type  Condition being treated  Stimulant and dose  Public sector clinic  Acknowledgement section  Authorised stimulant practitioner

Public sector clinics  Registered public sector clinics  Public sector clinics may apply to be registered as stimulant prescribing clinics by filling out an ‘Application to register a public clinic’ form  An authorised practitioner or senior staff member must be nominated by the clinic to liaise with the WA Department of Health  This allows submission of notifications on behalf of the clinic, allowing prescribing to occur by any authorised prescriber with access to patient notes Indicate: 1.If Patient is currently being treated at a registered public clinic 2.Name of clinic

‘Notification of Treatment using Stimulant Medication’ form  Patient details  Notification type  Condition being treated  Stimulant and dose  Public sector clinic  Acknowledgement section  Authorised stimulant practitioner

Acknowledgement section  Indicate in all cases:  Patient/parent/guardian name  Patient signature except for re-notifications and terminations and date  Practitioner signature and date  Necessary to ensure patient understands that information will be provided to the Department of Health

‘Notification of Treatment using Stimulant Medication’ form  Patient details  Notification type  Condition being treated  Stimulant and dose  Public sector clinic  Acknowledgement section  Authorised stimulant practitioner

Authorised stimulant prescriber  Indicate: 1.Authorised stimulant prescriber details and 2. Nominated co-prescriber if applicable Practitioner responsibility: Be familiar and comply with the Code Must have a Stimulant prescriber number Agree to participate in clinical audits May nominate a co-prescriber but must ensure they are aware of the patient’s current treatment regime Co-prescriber: Nominated by the authorised prescriber May not change details of a patients treatment, as only the authorised practitioner may do so Annual review by authorised prescriber required

Pharmacist responsibility  The pharmacist must ensure that  Scripts dispensed are within legal requirements for an Schedule 8 prescription and comply with WA Department of Health policy and legislation, Poisons Act and Poisons Regulations and the Pharmaceutical Benefits Scheme (PBS)  Repeat prescriptions must be retained at the pharmacy

Stimulant prescription requirements  An authorisation to prescribe a stimulant medication for patients who fall outside the criteria of the Code, is granted by the Chief Executive Officer (CEO) of the WA Department of Health and is separate to the PBS authority prescription which is a commonwealth funded scheme  Authorised practitioners are required to specify intervals between prescription repeats  Prescriptions are valid for six months from the date they are written  Non-stimulant medication such as atomoxetine does not require notification to the WA Department of Health

Related information and further enquiries  More information can be found on the Department of Health website  Under the Stimulant Regulatory Scheme at  For further enquiries on stimulant prescribing contact:  Pharmaceutical Services, Department of Health on